Ovid Therapeutics (OVID) Shares Outstanding (Weighted Average) (2016 - 2026)

Ovid Therapeutics has reported Shares Outstanding (Weighted Average) for 11 years, with the latest figure at $136.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 10893611.44% year-over-year to $136.2 million; the trailing twelve-month figure through Mar 2026 stood at $136.2 million (up 10893611.44% YoY), and the FY2025 full-year result was $1171.0, down 100.0% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $136.2 million, up from $67.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $136.2 million in Q1 2026, with the low at $1250.0 in Q3 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $61.8 million across 5 years, with a median of $70.5 million in 2023.
• Annual changes were most pronounced in 2025 — Shares Outstanding (Weighted Average) slumped 100.0% — and 2026, when it surged 10893611.44%.
• Ovid Therapeutics' Shares Outstanding (Weighted Average) stood at $70.4 million in 2022, then gained by 0.22% to $70.6 million in 2023, then increased by 0.46% to $70.9 million in 2024, then fell by 5.03% to $67.3 million in 2025, then soared by 102.21% to $136.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $136.2 million (Q1 2026), $67.3 million (Q4 2025), and $1250.0 (Q3 2025), per Business Quant data.